Toward predicting drug-induced liver injury: Parallel computational approaches to identify multidrug resistance protein 4 and bile salt export pump inhibitors

Drug Metabolism and Disposition

Volumn 43, Issue 5, 2015, Pages 725-734

  Welch, Matthew A ^a   Köck, Kathleen ^b   Urban, Thomas J ^a,b   Brouwer, Kim L R ^b   Swaan, Peter W ^a  

^a DUKE UNIVERSITY   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACECAINIDE; ACICLOVIR; ALFENTANIL; AMIKACIN; BILE SALT EXPORT PUMP INHIBITOR; CAMPTOTHECIN; CHLORAMPHENICOL; CHLORPROMAZINE; CITRININ; CLOPAMIDE; ETOPOSIDE; FENCLOZIC ACID; FUROSEMIDE; HALOPERIDOL; LOPINAVIR; METOCLOPRAMIDE; MULTIDRUG RESISTANCE PROTEIN 4 INHIBITOR; PARACETAMOL; PROTEIN INHIBITOR; QUERCETIN; RITONAVIR; ROFECOXIB; SELEGILINE; SITAGLIPTIN; SORAFENIB; SULINDAC; SURAMIN; TRIMETHOPRIM; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL; ABC TRANSPORTER; ABCB11 PROTEIN, HUMAN; ABCC4 PROTEIN, HUMAN; BILE ACID; MULTIDRUG RESISTANCE PROTEIN;

AREA UNDER THE CURVE; ARTICLE; COMPUTER MODEL; CONTROLLED STUDY; DRUG DATABASE; HYDROGEN BOND; HYDROPHOBICITY; PHARMACOPHORE; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; TOXIC HEPATITIS; ADVERSE DRUG REACTION; ANTAGONISTS AND INHIBITORS; BAYES THEOREM; CHOLESTASIS; COMPUTER SIMULATION; HUMAN; METABOLISM; RISK FACTOR;

ATP-BINDING CASSETTE TRANSPORTERS; BAYES THEOREM; BILE ACIDS AND SALTS; CHOLESTASIS; COMPUTER SIMULATION; DRUG-INDUCED LIVER INJURY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; RISK FACTORS;

EID: 84940374086     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.114.062539     Document Type: Article

References (27)

1. Abboud G and Kaplowitz N (2007) Drug-induced liver injury. Drug Saf 30:277-294.
2. Chai J, He Y, Cai SY, Jiang Z, Wang H, Li Q, Chen L, Peng Z, He X, and Wu X, et al. (2012) Elevated hepatic multidrug resistance-associated protein 3/ATP-binding cassette subfamily C 3 expression in human obstructive cholestasis is mediated through tumor necrosis factor alpha and c-Jun NH2-terminal kinase/stress-activated protein kinase-signaling pathway. Hepatology 55:1485-1494.
3. Dawson S, Stahl S, Paul N, Barber J, and Kenna JG (2012) In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans. Drug Metab Dispos 40:130-138.
4. Ekins S, Polli JE, Swaan PW, and Wright SH (2012) Computational modeling to accelerate the identification of substrates and inhibitors for transporters that affect drug disposition. Clin Pharmacol Ther 92:661-665.
5. Fattinger K, Funk C, Pantze M, Weber C, Reichen J, Stieger B, and Meier PJ (2001) The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: A potential mechanism for hepatic adverse reactions. Clin Pharmacol Ther 69:223-231.
6. Fawcett T (2006) An introduction to ROC analysis. Pattern Recognit Lett 27:861-874.
7. Fukuda Y, Takenaka K, Sparreboom A, Cheepala SB, Wu C-P, Ekins S, Ambudkar SV, and Schuetz JD (2013) Human immunodeficiency virus protease inhibitors interact with ATP binding cassette transporter 4/multidrug resistance protein 4: A basis for unanticipated enhanced cytotoxicity. Mol Pharmacol 84:361-371.
8. Gradhand U, Lang T, Schaeffeler E, Glaeser H, Tegude H, Klein K, Fritz P, Jedlitschky G, Kroemer HK, and Bachmakov I, et al. (2008) Variability in human hepatic MRP4 expression: influence of cholestasis and genotype. Pharmacogenomics J 8:42-52.
9. Khandelwal A, Bahadduri PM, Chang C, Polli JE, Swaan PW, and Ekins S (2007) Computational models to assign biopharmaceutics drug disposition classification from molecular structure. Pharm Res 24:2249-2262.
10. Khandelwal A, Krasowski MD, Reschly EJ, Sinz MW, Swaan PW, and Ekins S (2008) Machine learning methods and docking for predicting human pregnane X receptor activation. Chem Res Toxicol 21:1457-1467.
11. Köck K, Ferslew BC, Netterberg I, Yang K, Urban TJ, Swaan PW, Stewart PW, and Brouwer KLR (2014) Risk factors for development of cholestatic drug-induced liver injury: inhibition of hepatic basolateral bile acid transporters multidrug resistance-associated proteins 3 and 4. Drug Metab Dispos 42:665-674.
12. Kostrubsky VE, Strom SC, Hanson J, Urda E, Rose K, Burliegh J, Zocharski P, Cai H, Sinclair JF, and Sahi J (2003) Evaluation of hepatotoxic potential of drugs by inhibition of bile-acid transport in cultured primary human hepatocytes and intact rats. Toxicol Sci 76:220-228.
13. Law V, Knox C, Djoumbou Y, Jewison T, Guo AC, Liu Y, Maciejewski A, Arndt D, Wilson M, and Neveu V, et al. (2014) Drug Bank 4.0: shedding new light on drug metabolism. Nucleic Acids Res 42:D1091-D1097.
14. Morgan RE, Trauner M, van Staden CJ, Lee PH, Ramachandran B, Eschenberg M, Afshari CA, Qualls CW Jr, Lightfoot-Dunn R, and Hamadeh HK (2010) Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci 118:485-500.
15. Morgan RE, van Staden CJ, Chen Y, Kalyanaraman N, Kalanzi J, Dunn RT 2nd, Afshari CA, and Hamadeh HK (2013) A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicol Sci 136:216-241.
16. Nagar S and Korzekwa K (2012) Commentary: nonspecific protein binding versus membrane partitioning: it is not just semantics. Drug Metab Dispos 40:1649-1652.
17. Noé J, Stieger B, and Meier PJ (2002) Functional expression of the canalicular bile salt export pump of human liver. Gastroenterology 123:1659-1666.
18. Obuchowski NA and Lieber ML (1998) Confidence intervals for the receiver operating characteristic area in studies with small samples. Acad Radiol 5:561-571.
19. Pedersen JM, Matsson P, Bergström CA, Hoogstraate J, Norén A, LeCluyse EL, and Artursson P (2013) Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci 136:328-343.
20. Ritschel T, Hermans SM, Schreurs M, van den Heuvel JJ, Koenderink JB, Greupink R, and Russel FG (2014) In silico identification and in vitro validation of potential cholestatic compounds through 3D ligand-based pharmacophore modeling of BSEP inhibitors. Chem Res Toxicol 27:873-881.
21. Rogers D, Brown RD, and Hahn M (2005) Using extended-connectivity fingerprints with Laplacian-modified Bayesian analysis in high-throughput screening follow-up. J Biomol Screen 10:682-686.
22. Scheffer GL, Kool M, de Haas M, de Vree JM, Pijnenborg AC, Bosman DK, Elferink RP, van der Valk P, Borst P, and Scheper RJ (2002) Tissue distribution and induction of human multidrug resistant protein 3. Lab Invest 82:193-201.
23. Stieger B, Fattinger K, Madon J, Kullak-Ublick GA, and Meier PJ (2000) Drug- And estrogeninduced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. Gastroenterology 118:422-430.
24. Teng S and Piquette-Miller M (2007) Hepatoprotective role of PXR activation and MRP3 in cholic acid-induced cholestasis. Br J Pharmacol 151:367-376.
25. Ung CY, Li H, Yap CW, and Chen YZ (2007) In silico prediction of pregnane X receptor activators by machine learning approaches. Mol Pharmacol 71:158-168.
26. Xia X, Maliski EG, Gallant P, and Rogers D (2004) Classification of kinase inhibitors using a Bayesian model. J Med Chem 47:4463-4470.
27. Zweig MH and Campbell G (1993) Receiver-operating characteristic (ROC) plots: A fundamental evaluation tool in clinical medicine. Clin Chem 39:561-577.